Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of BAY1747846 in Participants With Impaired Renal Function in Comparison to Matched Participants With Normal Renal Function
Latest Information Update: 23 Nov 2022
Price :
$35 *
At a glance
- Drugs Gadoquatrane (Primary)
- Indications CNS disorders
- Focus Pharmacokinetics
- Sponsors Bayer
- 18 Nov 2022 Status changed from active, no longer recruiting to completed.
- 18 May 2022 Planned End Date changed from 20 Dec 2022 to 9 Nov 2022.
- 18 Apr 2022 Status changed from recruiting to active, no longer recruiting.